Department of Oncology, Liuzhou People Hospital, Guangxi Medical University, Liuzhou, China.
Department of Pathology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China.
Front Immunol. 2021 Aug 26;12:724429. doi: 10.3389/fimmu.2021.724429. eCollection 2021.
Tumor-associated macrophages (TAMs) are pivotal for tumor progression and metastasis. We investigated the stromal CD86+TAM/CD163+TAM (CD86/CD163) ratio as a novel prognostic biomarker for stage II-III colorectal cancer (CRC). Two independently clinical cohorts of stage II-III CRC were retrospectively enrolled in this study. TAMs were detected using immunohistochemical staining for CD86 and CD163. The stromal CD86/CD163 ratio was calculated as a prognostic biomarker for recurrence-free survival (RFS) and overall survival (OS). Patients with a low CD86/CD163 ratio had shorter RFS (HR=0.193, <0.001) and OS (HR=0.180, <0.001) than patients with a high CD86/CD163 ratio in the training cohort. CD86/CD163 ratio may be an independent predictor for RFS (HR=0.233, <0.001) and OS (HR=0.224, <0.001) in the training cohort. We obtained equivalent results in the validation cohort. The CD86/CD163 ratio tends to have better predictive values than tumor stage in the training (AUC: 0.682 0.654, =0.538) and validation (AUC: 0.697 0.659, =0.586) cohorts. CD86/CD163 ratio effectively predicts RFS for stage II (HR=0.203, <0.001) and stage III CRC (HR=0.302, <0.001). CD86/CD163 ratio also effectively predicts RFS in CRC patients with adjutant chemotherapy (HR=0.258, <0.001) and without adjutant chemotherapy (HR=0.205, <0.001). The stromal CD86/CD163 ratio could be used for individual risk assessment of recurrence and mortality for stage II-III CRC. Together with tumor stage, this ratio will aid in the personal treatment.
肿瘤相关巨噬细胞（TAMs）在肿瘤进展和转移中起着关键作用。我们研究了基质 CD86+TAM/CD163+TAM（CD86/CD163）比值作为 II-III 期结直肠癌（CRC）的新型预后生物标志物。本研究回顾性纳入了两个独立的 II-III 期 CRC 临床队列。使用 CD86 和 CD163 的免疫组织化学染色检测 TAMs。计算基质 CD86/CD163 比值作为无复发生存（RFS）和总生存（OS）的预后生物标志物。与高 CD86/CD163 比值的患者相比，低 CD86/CD163 比值的患者 RFS（HR=0.193，<0.001）和 OS（HR=0.180，<0.001）更短。在训练队列中，CD86/CD163 比值是 RFS（HR=0.233，<0.001）和 OS（HR=0.224，<0.001）的独立预测因子。在验证队列中我们也得到了等效的结果。在训练队列中，CD86/CD163 比值在预测价值上优于肿瘤分期（AUC：0.682 0.654，=0.538）和验证队列（AUC：0.697 0.659，=0.586）。CD86/CD163 比值可有效预测 II 期（HR=0.203，<0.001）和 III 期 CRC（HR=0.302，<0.001）的 RFS。CD86/CD163 比值也可有效预测接受辅助化疗（HR=0.258，<0.001）和未接受辅助化疗（HR=0.205，<0.001）的 CRC 患者的 RFS。基质 CD86/CD163 比值可用于评估 II-III 期 CRC 的个体复发和死亡风险。与肿瘤分期一起，该比值将有助于个体化治疗。
